BOLLÉ-SAFETY
19.4.2021 10:32:04 CEST | Business Wire | Press release
Global eye protection specialist Bollé Safety now provides Trivex. A high-performance, high-technology prescription lens providing maximum security and great optical properties to ensure the best safety in a work environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419005013/en/
The best of CR39 and polycarbonate in addition to unique features.
Bollé Safety’s latest lens material combines CR39’s lightness and polycarbonate’s durability. With a featherweight density (1,11g/cm3), Trivex is the lightest corrective lens material on the market. It also offers very good optical properties, superior to polycarbonate. The Trivex technology corrects some drawbacks traditionally attached to CR39 and polycarbonate. The lens is 20% thinner than CR39 and is shatterproof. Unlike polycarbonate, it is chemical and solvent resistant, making it safe to operate in a variety of work environments. Special new features include a 100% efficient UV filter that absorbs the totality of UVA and UVB for even better eye protection. And to ensure long-lasting aesthetics, the lens doesn’t turn yellow over time.
Why go to Bollé Safety to switch to Trivex?
Trivex properties are so high-performing that its technology was initially used for military purposes. With half of the global population over 20 years old suffering from vision problems, companies have a crucial interest in providing their workers with safety prescription eyewear that ensures optimal protection. Poor vision can lead to massive productivity losses and classic safety eyewear is not a one-size-fits-all product. Did you know that 90% of eye injuries could be prevented with proper protection and care? Wearing adapted and fitted eyewear can be a game-changer for professionals. Bollé Safety offers several ranges of products for plano and prescription lenses, so everyone can have perfect vision and safe working conditions. Bollé Safety’s latest frames, “KLASSEE” and “KURT”, make the most out of the Trivex technology. Thanks to Bollé’s unique global expertise, the KLASSEE model combines bio-sourced materials with side protections on the top and on the bottom of the frames. KURT is a great option with adjustable reinforced arms and an athletic frame for even more protection. The translucent front has been smoked to optimize side vision without being blinded. Lightweight and flexible, Bollé Safety glasses ensure a comfortable and secure experience and diminish risks in the work environment.
For more information, visit https://bit.ly/3e0A43j
About Bollé Safety.
Bollé Safety, the global brand for eye protection. Over our 130 years of existence, we have created more than 500 models of safety glasses. With a wide range of innovative, comfortable, and protective safety and prescription eyewear, we are trusted with the protection of over 20 million workers’ vision in 100 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005013/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Experian Expands Agent Trust Partner Ecosystem with Akamai to Advance Trusted AI Driven Commerce15.5.2026 15:00:00 CEST | Press release
Collaboration strengthens secure, scalable agentic commerce and supports emerging Know Your Agent standards Experian today announced that Akamai Technologies has joined its growing partner ecosystem, designed to further advance secure, trusted AI driven commerce through the Experian Agent Trust™ framework, alongside partner Skyfire supporting emerging payment innovation. As AI agents begin to search, decide, and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer directly initiated by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust is designed to address this challenge by establishing identity, accountability, and trust in agent driven interactions. “Trust, security, and performance must scale alongside the growing role of AI agents in digital commerce,” said Kathleen Peters,
The LYCRA Company and Dukane Advance Ultrasonic Bonding for Nonwovens at INDEX™ 2615.5.2026 14:00:00 CEST | Press release
LYCRA FUSION™ Fiber for Personal Care Applications Debuts The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the personal care industry, and Dukane, a manufacturer of ultrasonic bonding technologies for the hygiene and nonwovens market, are showcasing their latest co-developed advances in ultrasonic bonding at INDEX™ 26, taking place in Geneva, Switzerland, from May 19–22. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515514441/en/ Join The LYCRA Company and Dukane at INDEX™ 26 in Geneva, as they showcase their latest advances in ultrasonic bonding for nonwovens, including new LYCRA FUSION™ fiber for personal care that delivers superior snapback. Since 2014, both companies have collaborated to advance ultrasonic bonding solutions that help diaper manufacturers improve product softness, fit, and performance while reducing energy consumption, material waste, and maintenance costs. Ultrason
Vecima to Highlight Next-Generation 50G-PON, DOCSIS® 4.0 vCMTS, AI & Automation, and Monetizable Streaming at ANGA COM 202615.5.2026 13:45:00 CEST | Press release
Vecima Networks Inc. (TSX: VCM) will highlight its leadership in next-generation broadband at ANGA COM 2026, showcasing AI-powered network operations, cloud-native DOCSIS® 4.0 access, and scalable fiber solutions. Anchored by the Entra® vCMTS platform, Automation, and All-PON™ innovations, Vecima is enabling operators to automate operations, improve reliability, and accelerate the evolution to converged cable and fiber networks. Delivering on Next-Generation PON With Entra All-PON™, Vecima is enabling future-ready fiber networks with a straightforward migration path from today’s 10G technologies to 50G-PON, ensuring long-term scalability and investment protection. The new Entra EPS1650 All-PON Shelf supports 50G-PON, XGS-PON, 10G-EPON, GPON, and EPON services. As a follow-on to Vecima's industry-first demonstration of a single port supporting 50G ITU PON and 10G-EPON in a Remote OLT, the EPS1650 brings that same single-port investment-protection path to GPON and XGS-PON operators in a
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
